Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Mizuho Financial Group Inc. Sponosred ADR (Japan) — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.17 (market cap $124.07B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 14× Kymera Therapeutics Inc. Common Stock's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.79% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Mizuho Financial Group Inc. Sponosred ADR (Japan) for 6 Days on average.
| KYMR | MFG | |
|---|---|---|
Market Cap | $8.88B | $124.07B |
Volume | 1,028,790 | 3,230,414 |
Sector | Health | Financials |
52-Week High | $127.31 | $11.45 |
52-Week Low | $55.80 | $6.23 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.27B | $34.39T |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mizuho Financial Group (MFG) trades at $10.60, up slightly by 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.22 exceeding the $0.17 estimate. Revenue grew to $3.65T in 2025, with a net income margin of 30.42% and a P/E ratio of 14.96, indicating reasonable valuation. Recent news highlights institutional stake adjustments and positive CRA ratings.
MFG presents a mixed outlook; earnings momentum and solid profitability support upside, but bearish technicals and analyst caution (60% hold rating) suggest near-term pressure. Key risks include declining cash flow trends and rising debt-to-asset ratio, while institutional interest and dividend growth potential offer opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Mizuho Financial Group Inc. Sponosred ADR (Japan)
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →
